Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study-Reference-Cited by-同舟云学术

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

Published:2013-08 Issue:9 Volume:14 Page:901-908
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Chawla Sant,Henshaw Robert,Seeger Leanne,Choy Edwin,Blay Jean-Yves,Ferrari Stefano,Kroep Judith,Grimer Robert,Reichardt Peter,Rutkowski Piotr,Schuetze Scott,Skubitz Keith,Staddon Arthur,Thomas David,Qian Yi,Jacobs Ira

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Giant cell tumor of bone;Mendenhall;Am J Clin Oncol,2006

2. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India;Gupta;Ann Diagn Pathol,2008

3. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone;Alberghini;Virchows Arch,2010

4. Giant-cell tumour of bone;Szendroi;J Bone Joint Surg Br,2004

5. DeVita, Hellman, and Rosenberg's cancer: principles and practices of oncology;DeVita,2008

Cited by 467 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histological and immunohistochemical analyses of osteoclast maturation in giant cell tumor of bone;Pathology - Research and Practice;2024-02

2. The Risk of Neurological Deterioration While Using Neoadjuvant Denosumab on Patients with Giant Cell Tumor of the Spine Presenting with Epidural Disease: A Meta-Analysis of The Literature;The Spine Journal;2024-01

3. Clinical outcome of extended curettage with postoperative denosumab administration for the treatment of Campanacci Grade III giant cell tumors of the extremities;2023-12-20

4. Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document;The Journal of Clinical Endocrinology & Metabolism;2023-12-02

5. Current indications for denosumab in benign bone tumours;EFORT Open Reviews;2023-12-01